Platelet count > 100,000/mm^3 =< 2 weeks prior to randomizationXx_NEWLINE_xXPlatelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count ? 60,000/mm3Xx_NEWLINE_xX* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8 g/dLXx_NEWLINE_xXPlatelet count >= 100,000/mL within 28 days prior to registrationXx_NEWLINE_xXWithin 6 weeks prior to randomization: Platelet count must be >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 mcl obtained within 28 days prior to sub-study registrationXx_NEWLINE_xXPlatelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXRe-registration: platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mcLXx_NEWLINE_xXPlatelet count >= 100,000/uL, obtained within 4 weeks prior to randomizationXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibilityXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXObtained within 28 days prior randomization: platelet count must be >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3, within 4 weeks of randomizationXx_NEWLINE_xXPlatelet (PLTs) count >= 100,000/mm^3 obtained =< 21 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 90 days prior to step 1 registrationXx_NEWLINE_xXPlatelet greater than or equal to 100,000/mclXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) for patients with solid tumors without bone marrow involvementXx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count (PLT) >= 100,000/uL (>= 30 X 10^9/L), within 14 days of registrationXx_NEWLINE_xXPlatelet count > 100,000/mclXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >=100,000/ulXx_NEWLINE_xXPlatelet count >= 50,000/ul; for patients with >= 50% plasma cell involvement of the bone marrow, platelet count >= 30,000/ul is acceptableXx_NEWLINE_xXPlatelet count of >= 100,000/mm^3Xx_NEWLINE_xXPlatelet Count ? 100,000/?LXx_NEWLINE_xXPlatelet count ? 50,000/?L, with or without transfusion or cytokine supportXx_NEWLINE_xXObtained =< 21 days prior to registration: Platelet (PLT) >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/ul (>= 100,000 per mm^3) must be met within 28 days of C1D1Xx_NEWLINE_xXObtained =< 14 days prior to registration: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/ul (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)Xx_NEWLINE_xXPlatelet count of >= 100,000/uLXx_NEWLINE_xXPlatelet count 100,000 (plt/mm3)Xx_NEWLINE_xXPlatelet count > 100,000/µlXx_NEWLINE_xXPlatelet count ? 100,000/?LXx_NEWLINE_xXPlatelet count at least 100,000/mm3.Xx_NEWLINE_xXPlatelet count must be greater than or equal to 100,000/mm3; andXx_NEWLINE_xXPlatelet count > 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uL, within 14 days of registrationXx_NEWLINE_xXPlatelet count >= 50,000/uLXx_NEWLINE_xXPlatelet count > 25,000/mm3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3, performed within 14 days of treatment initiationXx_NEWLINE_xXPlatelet count (PLT) < 100,000/ul orXx_NEWLINE_xXPlatelet count < 100,000/µLXx_NEWLINE_xXPlatelet count >= 50,000/mm^3; note: platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count > 100,000 cells/mcLXx_NEWLINE_xXPlatelet count < 100,000/uL without full-dose anticogulation therapyXx_NEWLINE_xXPlatelet count < 150,000/uL with ongoing full-dose anticoagulation therapyXx_NEWLINE_xXPlatelet (PLT) count greater than or equal to 100,000/µLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 per mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count <150,000/mm3Xx_NEWLINE_xXPlatelet count ? 100,000/mm^3Xx_NEWLINE_xXplatelet count must be ? 100,000/mm3; andXx_NEWLINE_xXPlatelet count ? 50,000/µLXx_NEWLINE_xXObtained within 14 days prior to registration: Platelet count >= 150,000/uLXx_NEWLINE_xXPlatelet count >= 100,000 mm^3 within 14 days of enrollment to trialXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count is >= 50,000/mm^3 (<= 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count of >= 100,000/mm^3 before starting therapyXx_NEWLINE_xXEvident myeloid and platelet engraftment: Absolute neutrophil count (ANC) > 1000/mm^3 and platelet count > 25,000/ mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3 (100 x 10^9/L). Must not have required transfusion of platelets within 1 week of baseline platelet count assessment.Xx_NEWLINE_xXPlatelet count >= 100,000 platelet/mm^3 (100 × 10^9/L)Xx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Platelet count: >= 100 x 10^9/L (100,000/mm^3) within 2 weeks of registrationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Platelet count: >= 100 x 10^9/L (100,000/mm^3) within 2 weeks of registrationXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000 cells/mm^3 (50 x 10^9/L) at least 3 weeks prior to screening unless attributable to disease; platelet count >= 20,000 cells/mm^3 is permissible if due to diseaseXx_NEWLINE_xXObtained =< 35 days prior to registration: platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000 cells/mm3Xx_NEWLINE_xXPlatelet count >= 100,000 /mm^3Xx_NEWLINE_xXPlatelet count > 50,000 cells/mm^3 (50 x 10^9/L)Xx_NEWLINE_xXPlatelet count > 50,000/µLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count ? 100 x 10?/L (?100,000/cubic millimeters)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (performed within 14 days of treatment initiation)Xx_NEWLINE_xXPlatelet count < 100,000/µLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count > 100,000/uLXx_NEWLINE_xXPlatelet count >= 50,000/mm^3, obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mcLXx_NEWLINE_xXPlatelet count ? 100,000, hemoglobin ? 9 g/dLXx_NEWLINE_xXPHASE I: Platelet count >= 100,000/uLXx_NEWLINE_xXPHASE IB: Platelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count > 100,000 cells/mm^3Xx_NEWLINE_xXOBTAINED =< 7 DAYS PRIOR TO REGISTRATION: Platelet (PLT) >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 =< 28 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1,000/mm^3 without growth factor support and platelet count ? 75,000/mm^3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before randomization.Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3 in the absence of bone marrow involvement; patients with bone marrow involvement only require a platelet count of >= 30,000/mm^3Xx_NEWLINE_xXPlatelets >= 100,000/mm^3 transfusion independent (no platelet transfusion one week prior to enrollment)Xx_NEWLINE_xXPlatelet count ? 100,000/?L,Xx_NEWLINE_xXPlatelet count of >= 100,000/uLXx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count (PLT) > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mcLXx_NEWLINE_xXPlatelet count > 100,000/ul within four weeks of enrollmentXx_NEWLINE_xXPlatelet count >100,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of at least 100,000/L (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/?l (except in hepatocellular carcinoma patients with portal hypertension for whom a platelet count > 70,000/ul is allowed)Xx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet Count ? 100,000/mlXx_NEWLINE_xXPlatelet count >= 100,000/mcL, within 16 days of starting therapyXx_NEWLINE_xXPlatelet count: >= 50,000 (transfusion independent; >= 7 days from last transfusion)Xx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uL.Xx_NEWLINE_xXTREATMENT WITH SJCAR19: Platelet count > 20,000/uL (can be transfused)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).Xx_NEWLINE_xXPlatelet count < 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXShould be performed within 10 days of treatment initiation: platelet count ? 100 x 10^9/L (?100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/uL without transfusional support in the previous 7 daysXx_NEWLINE_xXPlatelet count > 100,000/lXx_NEWLINE_xXPlatelet count ?100,000/mm3Xx_NEWLINE_xXPlatelet count < 50,000/mm^3, per PI discretion if thought to be related to underlying myelomaXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000/mm^3Xx_NEWLINE_xXPlatelet count of > 100,000/mm^3LXx_NEWLINE_xXPlatelet count ? 50,000/uL, with or without transfusion supportXx_NEWLINE_xXPlatelet count >= 25,000/mm^3Xx_NEWLINE_xXObtained =< 14 days prior to registration: Platelet (PLT) >= 100,000 uLXx_NEWLINE_xXPlatelet (Plt) < 120,000/mm^3Xx_NEWLINE_xXWithin 7 days of enrollment and with 24 h of starting lymphodepleting chemotherapy: Platelet count >= 100,000/mm^3.Xx_NEWLINE_xXPlatelet count ? 100,000/mm3 without transfusion.Xx_NEWLINE_xXPlatelet count of greater than or equal to 100,000/mcLXx_NEWLINE_xXWithin 28 days prior to treatment start: Platelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count >= 100,000 / ml obtained =< 14 days prior to study initiationXx_NEWLINE_xXSTRATUM A: Platelet count >= 50,000/mm^3 without support of a platelet transfusion within 7 days of the testXx_NEWLINE_xXSTRATUM B: Platelet count >= 50,000/mm^3 without support of a platelet transfusion within 7 days of the testXx_NEWLINE_xXSTRATUM C: Platelet count >= 50,000/mm^3 without support of a platelet transfusion within 7 days of the testXx_NEWLINE_xXPlatelet count >= 30,000/uLXx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 x 10^9/microliterXx_NEWLINE_xXPlatelet < 100,000/mcLXx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXSTUDY TREATMENT: Platelet count >= 100,000/uL within 14 days prior to the first study treatment.Xx_NEWLINE_xXResearch participant platelet count must be > 100,000; however, if platelet level is between 75,000-99,000, then CAR T-cell infusion may proceed after platelet transfusion is given and the post transfusion platelet count is > 100,000Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/uL (no platelet transfusion within 7 days prior to obtaining laboratory result)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 /uL)Xx_NEWLINE_xXPlatelet count =< 100,000 x 10^9/uL at the screening visitXx_NEWLINE_xXPlatelet count: < 100,000 cell/dLXx_NEWLINE_xXPlatelet count > 100,000/uL without platelet transfusion within the past 7 daysXx_NEWLINE_xXPlatelet count ? 100,000/mm^3 (100 × 10^9/L) obtained ? 14 days prior to randomizationXx_NEWLINE_xXPlatelet count < 50,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXObtained within 14 days of the first study treatment: Platelet count > 100,000/uLXx_NEWLINE_xXPlatelet count >= 100 000/mm3 (within 16 days before starting therapy)Xx_NEWLINE_xXPlatelet count >= 100 000/mm^3 (within 16 days before starting therapy)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet (PLT) count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXObtained =< 14 days prior to registration: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count >= 100,000/µL.Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXObtained =< 14 days prior to registration: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count greater than 50,000/µLXx_NEWLINE_xXWithin 7 days prior to administration of study treatment: Platelet count >= 100 x 10^9/L (unless due to bone marrow infiltration by tumor, in which case platelet >=50,000/ mm^3 is allowed).Xx_NEWLINE_xXPlatelet count ? 100,000/mm3 (transfusion independent defined as no platelet transfusion within 7 days and recovery from nadir)Xx_NEWLINE_xXPlatelet count ? 100,000/?LXx_NEWLINE_xXPlatelet count of >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXThrombocytosis defined as platelet count > 1,200,000/mcLXx_NEWLINE_xXPlatelet count at least 100,000/mm^3 or at least 100 x 10^9/LXx_NEWLINE_xXObtained within 14 days of the first study treatment: Platelet count > 100,000/uLXx_NEWLINE_xXWithin 7 days (+ 3 day window) of enrollment: Platelet count >= 100 x 10^9/L (> 100,000 per mm^3)Xx_NEWLINE_xXREP ELIGIBILITY: Platelet count greater than or equal to 100,000/mcLXx_NEWLINE_xXCHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Platelet count greater than or equal to 100,000/mcLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet >= 100,000 / mcLXx_NEWLINE_xXPlatelet counts >=100,000/uL (without transfusion support) results within 7 days before study drug administrationXx_NEWLINE_xXPlatelet count >= 50,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>100,000 per mm^3).Xx_NEWLINE_xXPlatelet count < 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count > 50,000 cells/mm^3 (50 x 10^9/L)Xx_NEWLINE_xXObtained =< 28 days prior to registration: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^2Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelets > 100,000/µL. Patients with ? 100,000 platelet count may be allowed into the study on a case-by-case basis after consultation with the Medical Monitor.Xx_NEWLINE_xXplatelet count greater than 50,000/µLXx_NEWLINE_xXPlatelet count ?100,000 /mm3;Xx_NEWLINE_xXPlatelet count >= 100,000/ul within 14 days of cycle 1 day 1Xx_NEWLINE_xXPlatelet count >= 50,000/microliterXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1): platelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3 based on CBC/differential within 14 days prior to Step 2 registrationXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count < 100,000/mm^3 at the time of screeningXx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3)Xx_NEWLINE_xXWithin 14 days prior to cycle 1 day 1 of treatment: Platelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count of greater than 20,000/ul, with no platelet transfusion in prior 2 weeksXx_NEWLINE_xXPlatelet count >= 100,000Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count (PLT) >= 100,000/uL obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet >= 30,000 cells/mm^3Xx_NEWLINE_xXPHASE I: Subjects must have absolute neutrophil count (ANC) > 1,000 for 3 days and platelet transfusion independence as defined as a platelet count > 20,000 for 7 daysXx_NEWLINE_xXPHASE II: Subjects must have ANC > 1,000 for 3 days and platelet transfusion independence as defined as a platelet count > 20,000 for 7 daysXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent defined as not receiving platelet transfusions within a 7 day period prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) within 14 days of registrationXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count <100,000/mm3Xx_NEWLINE_xXPlatelet >100,000/ mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 obtained =< 7 days prior to registrationXx_NEWLINE_xXPlatelet count greater than or equal to 100,000/uLXx_NEWLINE_xXPlatelet count ? 50,000/ mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (within 16 days of enrollment)Xx_NEWLINE_xXPlatelet count greater than or equal to 55,000/mm^3 without transfusion supportXx_NEWLINE_xXPlatelet count < 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3).Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 100,000/uL; for patients with hematologic malignancies, platelet count >= 75,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uL; for patients with hematologic malignancies, platelet count >= 75,000/uLXx_NEWLINE_xXFULL STUDY INCLUSION CRITERIA: Platelet count >= 75,000/mm^3, without platelet transfusion within 3 weeks before the start of study treatmentXx_NEWLINE_xXPerformed within 14 days (+ 3 working days) prior to registration: Platelet count of > 100,000/mm^3 (may be reached by transfusion).Xx_NEWLINE_xXPlatelet count of >= 100,000/mm^3 (Note: Transfusion or growth factor may be used for eligibility outside of 7 days)Xx_NEWLINE_xXPlatelet count >=25,000/mm^3 [25 x 10^9/L]Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count (plt) >= 100,000/ uL (obtained within 28 days prior to first study treatment)Xx_NEWLINE_xXWithin 14 days of registration: Platelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3) within 28 days prior to study registrationXx_NEWLINE_xXPlatelet count ? 100,000/uL within 14 days prior to the first study treatment (cycle 1, day 1)Xx_NEWLINE_xXObtained =< 7 days prior to registration: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXWithin 14 days prior to planned start of treatment: Platelets >= 100,000/mm^3\r\n* Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvementXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 125,000/ul prior to biopsy; platelet count >= 100,000/ul prior to infusionXx_NEWLINE_xXPatients must have a platelet count >= 100,000 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 3 months prior to randomizationXx_NEWLINE_xXPlatelet count of >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet (PLT) >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXWithin 60 days prior to registration, hematologic minimal values: platelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 50,000 cells/mm^3 (50 x 10^9/L)Xx_NEWLINE_xXPlatelet count >= 100,000/ mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000 cells/uLXx_NEWLINE_xXPlatelet count >= 100,000/mcLXx_NEWLINE_xXPHASE II: Platelet count >= 100,000/mcLXx_NEWLINE_xXObtained =< 14 days prior to randomization: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/uLXx_NEWLINE_xXPlatelet count < 100,000/mm^3Xx_NEWLINE_xXCompleted within 60 days of surgery: Platelet count ? 100,000/mmXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 90 x 10^9/L (100,000/mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of >= 95,000/uLXx_NEWLINE_xXPlatelet count of >= 85,000/ulXx_NEWLINE_xXPlatelet count of >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)Xx_NEWLINE_xXPART 2 GROUP 1 INCLUSION CRITERIA: Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPART 2 GROUP 3 INCLUSION CRITERIA: Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000 (platelet [plt]/mm^3), with or without transfusion support; NOTE: If the patient’s bone marrow biopsy shows greater than or equal to 50% plasma cells, the platelet count should be > 3 0,000 plt/mm^3 (transfusion support or growth factor support is acceptable)Xx_NEWLINE_xXPlatelet count < 50,000/microLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 3 months prior to randomizationXx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count < 100,000/mm^3Xx_NEWLINE_xXPlatelet count greater than or equal to 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL independent of transfusion and or growth factors within 3 months prior to enrollmentXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXObtained =< 14 days prior to registration: Platelet (PLT) >= 100,000Xx_NEWLINE_xXPlatelet count >= 100,000/uL within 30 days prior to C1D1Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mcLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count greater than or equal to 45,000/mm^3 without transfusion supportXx_NEWLINE_xXObtained =< 14 days prior to registration: Platelet count >= 30,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 /mm^3Xx_NEWLINE_xXPlatelet count > 50,000/mLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100 x 10^9/L (? 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 70,000 cells/mm^3 if marrow plasmacytosis < 50%; platelet count >= 30,000 cells/mm^3 if marrow plasmacytosis >= 50%Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100 x 100^9/LXx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 within 7 days prior to enrollment \r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXWithin 3 months of registration: Platelet count (plt) >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollmentXx_NEWLINE_xXPlatelet counts > 100,000/mm^3 (without support)Xx_NEWLINE_xXPlatelet count >= 50,000/uL; platelet transfusions are not allowed within 14 days of platelet assessmentXx_NEWLINE_xXPlatelet count >= 50,000/ul (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXARM A COHORT 1: Platelet count >= 100,000/ulXx_NEWLINE_xXARM B COHORT 2: Platelet count >= 100,000/ulXx_NEWLINE_xXARM B COHORT 3: Platelet count >= 100,000/ulXx_NEWLINE_xXARM C COHORT 4: Platelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count < 100,000 per mm^3Xx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3 (patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or > than 20,000/mm^3; these patients should be discussed with either the PI or Co-PI of the study for final approval)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count greater than or equal to 100,000/microL (transfusion independent)Xx_NEWLINE_xXPlatelet count > 100,000/lXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXA mean platelet count of < 30,000/?L, with no individual platelet count > 35,000/?L; or for those subjects receiving a constant dose of permitted treatments for ITP: a mean platelet count < 50,000/?L, with no count greater than 55,000/?L. (Note: The mean platelet count must be determined based on 2 platelet counts including one obtained within ? 7 days of first PRTX-100 dose and the other within ? 30 days of the first dose of PRTX-100.)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (no transfusion within 7 days of enrollment)Xx_NEWLINE_xXFor subjects with solid tumors without known bone marrow involvement: platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000/mm³.Xx_NEWLINE_xXMust be met within 28 days of C1D1: Platelet count >= 100,000/ulXx_NEWLINE_xXPlatelet (PLT) count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3; independent of transfusionXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 or >= 75,000/mm^3 if thrombocytopenia is attributed to B-NHL (involvement of bone marrow or due to splenomegaly or immune thrombocytopenic purpura); platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count >= 30,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000Xx_NEWLINE_xXPlatelet count >= 125,000 cells/mm^3 prior to biopsy; platelets >= 100,000 cells/mm^3 prior to infusionXx_NEWLINE_xXPlatelet count >= 60,000/ucl obtained within 28 days prior to registrationXx_NEWLINE_xXPlatelet count of >= 30,000Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXplatelet count must be greater than or equal to 100,000/mm3; andXx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3 or >= 100 bil/LXx_NEWLINE_xXPlatelet count >= 90,000/mm^3Xx_NEWLINE_xXResearch participant platelet count must be >= 100,000; however, if platelet level is between 75,000-99,000, then T-cell infusion may proceed after platelet transfusion is given and the post transfusion platelet count is >= 100,000Xx_NEWLINE_xXPlatelet count =< 100,000 per mm^3Xx_NEWLINE_xXWithin 2 weeks of enrollment: Platelet count, >= 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count: greater than or equal to 50,000 at least one week since last platelet transfusionXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of >= 100,000/LXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 platelet/mm^3 (100 × 10^9/L)Xx_NEWLINE_xXPlatelet count >= 80,000/uLXx_NEWLINE_xXPlatelet (PLT) >= 100,000/uL (obtained =< 7 days prior to registration)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXc. Platelet count ? 100,000/µLXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (100 × 10^9/L)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count greater than or equal to 100,000/mm^3 (Turnstile II)Xx_NEWLINE_xXPlatelet count <100,000/?LXx_NEWLINE_xXPatients must have an ANC ? 1,500/?l and a platelet count ? 100,000/?l obtained within 14 days prior to registration.Xx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/Xx_NEWLINE_xXRelapsed/refractory MCL: Platelet count >= 30,000/mm^3 (transfusion to reach platelet count allowed); (patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or > than 15,000/mm^3; these patients should be discussed with either the PI or Co-PI of the study for final approval)Xx_NEWLINE_xXNewly diagnosed MCL: Platelet count > 50,000/mm^3; patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or > than 15,000 /mm^3; (platelet transfusions are allowed; these patients should be discussed with either the PI or Co-PI of the study for final approval)Xx_NEWLINE_xXPlatelet count of > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 per mm^3 ANDXx_NEWLINE_xXPlatelet count < 100,000Xx_NEWLINE_xXPlatelet count >= 100,000 cells/uLXx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3 or >= 100 bil/LXx_NEWLINE_xXPlatelet count >= 25,000/ul (phase I only)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count greater than or equal to 100,000/mm^3 (Turnstile II)Xx_NEWLINE_xXPlatelet >= 100,000Xx_NEWLINE_xXPlatelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 50,000Xx_NEWLINE_xXPlatelet count of >= 100,000/mm^3Xx_NEWLINE_xXPlatelet (PLT) >= 100,000/mcLXx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000 /mm^3Xx_NEWLINE_xXPlatelet count >= 25,000/ulXx_NEWLINE_xXPlatelet count (PLT) >= 100,000/mm^3Xx_NEWLINE_xXObtained =< 28 days prior to randomization: \r\nPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000 cells/mm^3 (50 x 10^9/L), at screeningXx_NEWLINE_xXPlatelet count of >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 30,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL (may be a post transfusion value)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 within 7 days prior to starting treatmentXx_NEWLINE_xXPlatelet count must be >= 50,000Xx_NEWLINE_xXPlatelet > 125,000 platelet/mm^3Xx_NEWLINE_xXPlatelet count < 25,000/ulXx_NEWLINE_xXPlatelet count =< 25,000/?lXx_NEWLINE_xXPlatelet count < 100,000 cells/mm3.Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (repeat if more than 3 days before the first dose)Xx_NEWLINE_xXPlatelet count > 100,000/uL during screening evaluationXx_NEWLINE_xXPlatelet count >= 50,000 mm^3; platelet count should be independent of transfusions for at least 14 days for eligibilityXx_NEWLINE_xXPlatelet count ? 100,000/mm3 (IU: ? 100 × 109/L) (excluding measurements obtained within 7 days after a transfusion of platelets).Xx_NEWLINE_xXPlatelet count < 50,000 cells/mm3Xx_NEWLINE_xXOr platelet count < 50,000Xx_NEWLINE_xXPlatelet count >50,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 performed within 60 days of enrollmentXx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count ?100,000/mm3Xx_NEWLINE_xXPlatelet count ? 100,000/mm^3Xx_NEWLINE_xXWithin 14 days prior to randomization: Platelet count must be >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count ?100,000 cells/mm3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/ulXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count ?100,000 cells/mm3Xx_NEWLINE_xXPlatelet count ? 100 x 109/L (100,000/µL) without transfusionXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Platelet count >= 100,000 /mcL, within 14 days prior to first dose of pembrolizumabXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Platelet count >= 100,000 /mcL, within 14 days prior to first dose of pembrolizumabXx_NEWLINE_xXPlatelet count: >= 50,000/ul, transfusion independent (no platelet transfusions within 1 week)Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 100,000uL for patients with hematologic malignancies, platelet count >= 75,000/uL.Xx_NEWLINE_xXFor high risk and very high risk CLL-IPI (Arms A and B) only; obtained ? 30 days prior to randomization: Platelet count ? 100,000/mm^3Xx_NEWLINE_xXFor subjects with solid tumors without known bone marrow involvement: \r\n*Platelet count ? 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXObtained ? 14 days prior to registration: platelet count ? 75,000/mm^3 (NOTE: platelet transfusions in order to help patients meet eligibility criteria are not allowed)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3.Xx_NEWLINE_xXPlatelet count >= 100,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 and no transfusion in prior 4 weeks, within 28 days of day 0.Xx_NEWLINE_xXPlatelet count ? 100,000 cells/mm^3 ? 2 weeksXx_NEWLINE_xXObtained =< 21 days prior to registration: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/L (>=100,000 per mm^3).Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3), except for patients with HCC for whom a platelet count > 60,000 per mm^3 is allowedXx_NEWLINE_xXPlatelet count > 100,000/mm^3. Patients who have bone marrow infiltration by MCL are eligible if their platelet level is >= 50,000 /mm^3 independent of platelet transfusions.Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 50,000/ulXx_NEWLINE_xXPlatelet count >= 100,000 per mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 /mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 /mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 /mm^3Xx_NEWLINE_xXObtained =< 7 days prior to registration: Platelet count >= 100,000/uLXx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXWithin 7 days prior to study registration: Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (100 x 10^9 /L) obtained =< 28 days prior to registrationXx_NEWLINE_xXPlatelet count >= 25,000/mm^3 [25 x 10^9/L],Xx_NEWLINE_xXPlatelet count >= 100,000 plt/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3, obtained =< 7 days prior to registrationXx_NEWLINE_xXPlatelet count >= 50,000/uL; platelet transfusion is not permitted within 7 days of screeningXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count must be >= 100,000/mm^3 within 28 days before randomizationXx_NEWLINE_xXPlatelet count >= 50,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPerformed within 14 days prior to study: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count < 100,000/mm^3, orXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelets >= 100,000/mm^3 (transfusion independent (except for patients with marrow involvement by disease where there is no blood count requirement, except for platelet count which must be >= 25,000 prior to enrollment (can be achieved with transfusion)Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment); in NB patients with known bone marrow involvement relaxed platelet count eligibility requirement should be used: a platelet count of >= 20,000/mm that can be maintained with =< 1 platelet transfusion per weekXx_NEWLINE_xXPlatelet (PLT) >= 100,000Xx_NEWLINE_xXARM A: obtained =< 14 days prior to registration: \r\n* Platelet count >= 80,000/mm^3Xx_NEWLINE_xXARM B: obtained =< 14 days prior to registration: \r\n* Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXObtained within 14 days (or as stipulated) prior to study drug (treatment) administration: platelet count ? 50,000/ul (without platelet transfusion in the previous 5 days)Xx_NEWLINE_xXPlatelet count >= 150,000/ulXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 or >= 100 x 10^9/L (must be >= 7 days after most recent transfusion), obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000/ul (no platelet transfusion for more than 3 days)Xx_NEWLINE_xXPlatelet >= 100,000/ mm^3Xx_NEWLINE_xXObtained =< 7 days prior to registration: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mcLXx_NEWLINE_xXPlatelet (PLT) count ? 100,000/µLXx_NEWLINE_xXPlatelet count (PLT) >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of < 100,000Xx_NEWLINE_xXPlatelet >= 100,000/uLXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count: >= 50,000/mm^3, transfusion independent (no platelet transfusions within 1 week)Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000 per mm^3Xx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 mcl obtained within 28 days prior to Step 2 re-registrationXx_NEWLINE_xXPlatelet count > 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count > 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (obtained =< 14 days prior to registration)Xx_NEWLINE_xXPlatelet count >= 100,000 mcl obtained within 28 days prior to Step 2 re-registrationXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 or >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100,000 mcl obtained within 28 days prior to step 2 re-registrationXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL; for patients with hematologic malignancies, platelet count >= 75,000/uLXx_NEWLINE_xXFor patients with solid tumors without bone marrow involvement: platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)Xx_NEWLINE_xXPlatelet count (PLT) > 100,000/mm^3Xx_NEWLINE_xXPlatelet count greater than or equal to 45,000/mm^3 without transfusion supportXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXFor patients with solid tumors without bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXFor patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPatients on Part C with acute lymphoblastic leukemia: platelet count >= 20,000/mm^3 (may receive platelet transfusions); these patients must not be known to be refractory to red cell or platelet transfusionXx_NEWLINE_xXPlatelet count must be >= 50,000/mm^3 (not achieved by transfusion)Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count must be >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count < 100,000 / mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 20,000Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/ulXx_NEWLINE_xXPlatelet count greater than or equal to 100,000/mcLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXFor patients with solid tumors or ALCL without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPatients must have a platelet count >= 20,000/uL at the time of the initial evaluationXx_NEWLINE_xXPlatelet (PLT) = 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of greater than 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet =< 140,000Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count >= 130,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/ulXx_NEWLINE_xXPlatelet count >= 100,000/ULXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 within four weeks prior to randomizationXx_NEWLINE_xXPlatelet count ?100,000/µlXx_NEWLINE_xXPlatelet count > 80,000/mcLXx_NEWLINE_xXPlatelet count >= 100,000 cells/mcLXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count < 50,000/mm^3 within 21 days of initiation of protocol therapy for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or platelet count < 30,000/mm^3 for patients in whom >= 50% of bone marrow nucleated cells are plasma cells; transfusion is not allowed to meet platelet eligibility criteriaXx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Platelet count >= 100,000/mcL; these results must be obtained within 28 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mcL obtained within 28 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100,000 mcl obtained within 28 days prior to RE-TREATMENT registrationXx_NEWLINE_xXPlatelet count ? 100,000 cells/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm³Xx_NEWLINE_xXplatelet count >30,000 /?LXx_NEWLINE_xXPlatelet count >= 100,000/mm^3, obtained =< 21 days prior to registrationXx_NEWLINE_xXPlatelet ? 100,000 / uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count ? 100,000/mm^3Xx_NEWLINE_xXplatelet count must be greater than or equal to 100,000/mm3; andXx_NEWLINE_xXSUB-PROTOCOL AIM A: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count at least 100,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXPlatelet count >= 100 K/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count of >30,000/mm3Xx_NEWLINE_xXPlatelet count greater than or equal to 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count (untransfused) >= 30,000/uLXx_NEWLINE_xXPlatelet count less than 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet Count >= 100,000/mlXx_NEWLINE_xXPlatelet >= 100,000/ mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent)Xx_NEWLINE_xXPlatelet count ? 100,000/µLXx_NEWLINE_xXPresence of significant active bleeding or condition requiring maintenance of a platelet count > 50,000/uLXx_NEWLINE_xXPlatelet count > 30,000 K/uL independent of transfusion supportXx_NEWLINE_xXPlatelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXPlatelet >= 100 x 10^9/L (> 100,000 per mm^3), obtained within 14 days prior to first treatmentXx_NEWLINE_xXPlatelets >= 100,000 cells/mm^3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)Xx_NEWLINE_xXPlatelet count >= 100 000/mm^3 (within 16 days before starting therapy)Xx_NEWLINE_xXPlatelet count >= 100,000/mclXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count > 100,000/uL or > 75,000/uL if bone marrow (BM) involvement or splenomegalyXx_NEWLINE_xXWithin 28 days prior to signing informed consent: Platelet counts >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement with lymphoma, independent of transfusion support in either situationXx_NEWLINE_xXPlatelet count >= 50,000Xx_NEWLINE_xXPlatelet count > 30,000/mm^3Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 100,000/uL; for patients with hematologic malignancies, platelet count >= 75,000/uLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3; platelet transfusions are not allowed within 3 days before study enrollmentXx_NEWLINE_xXSubjects with evidence of mucosal or internal bleeding and/or platelet refractory (i.e., unable to maintain a platelet count >= 50,000 cells/mm^3)Xx_NEWLINE_xXPlatelet count: ? 100,000/mm3Xx_NEWLINE_xXPlatelet count =< 70,000/mm^3Xx_NEWLINE_xXPlatelet count > 50,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/ulXx_NEWLINE_xXPlatelets >= 100,000/mm^3 (unsupported, defined as no platelet transfusion within 7 days and recovery from nadir)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelet count ? 50,000/mm3 (? 30,000/mm3 if myeloma involvement in the bone marrow is > 50%. Subjects should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count < 75,000 cells/mm^3 at time of screening evaluation; transfusion may not be used to meet platelet eligibility criteria within 7 days of obtaining screening evaluationXx_NEWLINE_xXPlatelet count > 100,000/mm^3 (obtained =< 7 days prior to randomization)Xx_NEWLINE_xXPlatelet (PLT) count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 obtained =<14 days prior to randomizationXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count (PLT) >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) andXx_NEWLINE_xXPlatelet count > 75,000/mm^3; (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 1000/mm^3 [growth factor not allowed] or their platelet level is >= 50,000/mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXA platelet count of at least 100,000/mm^3 on at least 2 consecutive blood draws at least 1 week apart with results stable or trending upward is requiredXx_NEWLINE_xXPlatelet count >= 100,000/mLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet (PLT) >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/uLXx_NEWLINE_xXPHASE I: Platelet count >= 50,000 mm^3Xx_NEWLINE_xXPHASE II: Alternatively, with less BM involvement, an ANC >= 1000/mm^3, and platelet count >= 50,000 mm^3 is requiredXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1,000 per cubic milliliter (/mm^3) and platelet count ? 75,000/mm^3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before randomization.Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 x 10^9/LXx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/microliterXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criterion will not be allowedXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count < 50,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXplatelet count > 100,000/mm3Xx_NEWLINE_xXPlatelet count of < 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/uL without platelet transfusion within the past 7 daysXx_NEWLINE_xXThe platelet count must be at least 100,000/uLXx_NEWLINE_xXPlatelet count < 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mLXx_NEWLINE_xXPlatelet count ? 100,000/mm3Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count < 75,000 cells/mm^3 at time of screening evaluation; transfusion may not be used to meet platelet eligibility criteria within 7 days of obtaining screening evaluationXx_NEWLINE_xXPlatelet count greater than or equal to 100,000/uLXx_NEWLINE_xXWithin 30 days prior to initiation of protocol treatment: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count must be > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3 or >= 100 bil/LXx_NEWLINE_xXPlatelet count of >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/iLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm3Xx_NEWLINE_xXPlatelet count ?20,000/?L (transfusions to achieve this level are allowed). Subjects with a baseline platelet count of <20,000/?L due to underlying malignancy are eligible with Medical Monitor approval.Xx_NEWLINE_xXPlatelet > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (unsupported)Xx_NEWLINE_xXPlatelet count > 100,000Xx_NEWLINE_xXPlatelet count >= 50,000/uLXx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3 or >= 100 bil/LXx_NEWLINE_xXPlatelet count >= 20,000/ul without transfusion for 7 daysXx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3 or >= 100 bil/LXx_NEWLINE_xXPlatelet count of more than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 cell/mm^3Xx_NEWLINE_xXObtained within 2 weeks from study entry: Platelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count of less than 35,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uL obtained within 2 weeks prior to enrollmentXx_NEWLINE_xXPlatelet count =< 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/mcLXx_NEWLINE_xXSTEP 2 ENROLLMENT AND RANDOMIZATION: platelet count >= 100,000/mm^3 within 3 weeks of study entryXx_NEWLINE_xXPlatelet count >= 100,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count < 100,000/mLXx_NEWLINE_xXPlatelet count >= 25,000/ulXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (unless due to bone marrow infiltration by tumor in which case >= 50,000/ml are allowed)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXWithin one week of study entry: Platelet count at least 100,000 cells/mm^3Xx_NEWLINE_xXObtained within 14 days prior to registration: Platelet count >= 100,000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1000/mm^3 and platelet count ? 75,000/mm^3. Platelet transfusions to help participants meet eligibility criteria were not allowed within 3 days prior to randomization.Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 obtained =< 14 days prior to randomizationXx_NEWLINE_xXPlatelet count >= 100,000/mcLXx_NEWLINE_xXPlatelet count ? 100,000 /mm3Xx_NEWLINE_xXPlatelet count >= 50,000 /mm^3Xx_NEWLINE_xXPlatelet count at least 80,000 cells/mm^3Xx_NEWLINE_xXPlatelet count at least 100,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of >= 100,000/mm^3Xx_NEWLINE_xXPlatelet Count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/uL (platelet count must be assessed at least 7 days after a prior transfusion, if any)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,00 mm^3 independent of transfusion supportXx_NEWLINE_xXPlatelet count >= 100,000/mclXx_NEWLINE_xXPlatelet count of at least 100,000 per mcLXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count of >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count at least 100,000/mm^3 or at least 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100,000/mytm^3Xx_NEWLINE_xXPlatelet count >= 40,000Xx_NEWLINE_xXPatient has a platelet count of less than 50,000 within 14 days before enrollmentXx_NEWLINE_xXPlatelet count of  >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 20,000/mm^3 without transfusion support and no abnormal bleedingXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uL within 30 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count < 50,000 cells/mm^3 (50 x 10^9/L) independent of transfusion supportXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (> 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/ulXx_NEWLINE_xXPlatelet >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 90,000/mm^3 (part 1 & 2)Xx_NEWLINE_xXPlatelet count > 100,000 per microliterXx_NEWLINE_xXPlatelet count greater than or equal to 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of >= 100,000/microliters within 90 days prior to registrationXx_NEWLINE_xXPlatelet count < 100,000 either pre-operatively or post-operativelyXx_NEWLINE_xXPlatelet count < 100,000 /LXx_NEWLINE_xXPlatelet count >= 100,000 /mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count > 50,000/ulXx_NEWLINE_xXPlatelet count >= 150,000/uLXx_NEWLINE_xXA platelet count > 100,000/µLXx_NEWLINE_xXPlatelet count ? 100,000 cells/mm3Xx_NEWLINE_xXPlatelet count ?100,000 //mm3 (?100 × 109/L).Xx_NEWLINE_xXPlatelet count of < 50,000 ,Xx_NEWLINE_xXPlatelet count equal or greater than 50,000 mm^3 independent of platelet transfusionXx_NEWLINE_xXPlatelet count of > 100,000/ulXx_NEWLINE_xXPlatelet count 100,000/mLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3 (without platelet transfusion or myeloid growth factor support within two weeks of screening)Xx_NEWLINE_xXPatients must have platelet count >= 10,000/mm^3 within 72 hours of initiating the induction cycle (for patients with platelets < 10,000/mm^3 at baseline, platelet transfusion support is allowed which is institutional standard of care for AML)Xx_NEWLINE_xXPlatelet count ?100,000/?LXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/ulXx_NEWLINE_xXPlatelet count ? 100,000/?LXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mcLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count > 100,000 /mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000 (100 × 109/L) cells/mm3;Xx_NEWLINE_xXPlatelet count ? 50,000/?L;Xx_NEWLINE_xXPlatelet >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count must be >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXDONOR: platelet count 150,000 to 440,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXThrombocytopenia (platelet count ? 100,000/µL) at any time after signing informed consentXx_NEWLINE_xXPlatelet count > 50,000/mm^3Xx_NEWLINE_xXPlatelets: >= 100,000/mm^3 (transfusion independent defined as not receiving platelet transfusions within 7 days prior to registration)Xx_NEWLINE_xXPlatelet count > 100,000 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 50,000/?LXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet Count > 100,000/mm3Xx_NEWLINE_xXA platelet count of more than 100,000/mm^3Xx_NEWLINE_xXTREATMENT: Platelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/microliterXx_NEWLINE_xXPlatelet count >= 100,000 cells/mm3 without transfusion or growth factor requirementXx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet (PLT) >= 100,000/uLXx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 platelets/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 platelets/mm^3Xx_NEWLINE_xXPlatelet count must be >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count < 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count equal to or less than 100,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count <100,000/µL,Xx_NEWLINE_xXPlatelet count ? 100,000/mm3 (without platelet transfusion or growth factor support in the preceding 7 days);Xx_NEWLINE_xXPlatelet count > 100,000/µLXx_NEWLINE_xXPlatelet count greater than or equal to 100,000/mm^3Xx_NEWLINE_xXPlatelet count at least 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count <120,000/?L.Xx_NEWLINE_xXPlatelet count >= 75,000/uL for patients with solid tumors without bone marrow involvement (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment); platelet count >= 25,000/uL for patients with known bone metastatic disease (transfusions are permitted to reach the platelet criteria)Xx_NEWLINE_xXPlatelets ? 100,000 cells/?L (with no evidence that this platelet count was induced or supported by a platelet-stimulating agent)Xx_NEWLINE_xXPlatelet count < 100,000/µLXx_NEWLINE_xXPlatelet count of >= 100,000 mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uL (without transfusion within 2 weeks prior to cycle 1, day 1)Xx_NEWLINE_xXPlatelet count ? 100,000/mm3Xx_NEWLINE_xXPlatelet count ? 100,000 cells/mm3Xx_NEWLINE_xXPlatelet count 100.000 cells/mm3 (100 x 109/L)Xx_NEWLINE_xXPlatelet count >100,000 cells/mm3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count < 100,000 / mm^3Xx_NEWLINE_xXPlatelet count > 50,000/mm^3Xx_NEWLINE_xXPlatelet count < 100,000/mm3.Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 within 16 days of starting therapyXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/ulXx_NEWLINE_xXCROSSOVER (STEP 2) REGISTRATION: Platelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count ? 100,000/µLXx_NEWLINE_xXPlatelet count >=100,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000/mm3Xx_NEWLINE_xXPlatelet count ³ 100 × 109/L (100,000/mm3)Xx_NEWLINE_xXDoes the subject have a platelet count ? 100,000/mm3?Xx_NEWLINE_xXPlatelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count < 100,000 per mm3Xx_NEWLINE_xXPlatelet >= 100,000/uLXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXKnown platelet disorder, such as von Willebrand’s disease or baseline platelet count of < 100,000/mm^3Xx_NEWLINE_xXPlatelet count < 100,000 per mm3Xx_NEWLINE_xXPlatelet count > 100‚000/uLXx_NEWLINE_xXPlatelet count ? 100,000/mm3.Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 25000/mm^3Xx_NEWLINE_xXPlatelet count: 100,000/ul and transfusion independent (no platelet transfusions within 7 days of blood draw documenting eligibility)Xx_NEWLINE_xXCohort A: Platelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count ? 100,000/µLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (100 x 10^9/L)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet Count ? 100,000/mm3Xx_NEWLINE_xXPlatelet count ? 50,000/mm³ (? 30,000/mm³ if myeloma involvement in the bone marrow is > 50%) within 21 days prior to randomization. Patients should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.Xx_NEWLINE_xXPlatelet count >100,000/mm3.Xx_NEWLINE_xXPlatelet count of >= 100,000/uLXx_NEWLINE_xXPeripheral platelet count (PLT) >= 100,000Xx_NEWLINE_xXPlatelet count =< 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3Xx_NEWLINE_xXplatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet >= 100,000/mm3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 80,000/mm^3Xx_NEWLINE_xXPlatelet count greater than or equal to 25,000/uLXx_NEWLINE_xXPlatelet >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count < 100,000/mlXx_NEWLINE_xXPlatelet count > 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 mm^-3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement independent of transfusion support in either situationXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 20,000/mm^3 (may receive platelet transfusions); these patients must not be known to be refractory to red cell or platelet transfusionXx_NEWLINE_xXPlatelet count greater than or equal to 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelets > 100,000/mm^3 unless deemed likely related to lymphoma involvement in the bone marrow where minimum allowable platelet count will be 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000 mm^-3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 50,000/mm^3 and < 100,000/mm^3 within 14 days prior to study entryXx_NEWLINE_xXPlatelet count < 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uL (obtained within 28 days prior to the first study treatment)Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/ul (corrected if needed)Xx_NEWLINE_xXMost recent platelet count prior to surgery < 70,000/mclXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count > 100,000/mcLXx_NEWLINE_xXPlatelet count less than 20,000/microliterXx_NEWLINE_xXPlatelet count >= 100,000 cells/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/uLXx_NEWLINE_xXPlatelet count > 100,000Xx_NEWLINE_xXPlatelet count ? 100,000/mm3Xx_NEWLINE_xXPlatelet count > 100,000/uLXx_NEWLINE_xXObtained =< 30 days prior to randomization: Platelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000/mm3Xx_NEWLINE_xXPlatelet count > 100,000/ulXx_NEWLINE_xXPlatelet count >= 100,000, unless felt to be secondary to underlying mantle cell lymphomaXx_NEWLINE_xXPlatelet count >= 25,000 cells/mm^3 (25 x 10^9/L) independent of transfusion within 7 days of screeningXx_NEWLINE_xXPlatelet count <90,000/mLXx_NEWLINE_xXPlatelet count > 150,000/mm^3Xx_NEWLINE_xXPlatelet count (PLT) >= 100,000/mm^3Xx_NEWLINE_xXThrombocytopenia:\r\n* Defined as platelet count < 100,000/mcL\r\n* The patient will have had at least 2 complete blood counts (CBC) with platelet counts < 100,000/mcL separated by at least 4 weeks, and no platelet count >= 100,000/mcL in the prior 6 week period, despite (1) delay or (2) modification of chemotherapeutic regimen\r\n* A platelet count of > 100,000/mcL, that follows within 7 days of a platelet transfusion, will not make the patient ineligible, as long as one or more subsequent platelet counts confirms thrombocytopenia (< 100,000/mcL)\r\n* Patients have undergone bone marrow aspirate and biopsy, or peripheral blood test in the prior 3 months, without evidence of leukemia or myelodysplasia by fluorescent in situ-hybridization (FISH)\r\n* Dysplastic changes, based on morphology only, will not exclude the patient if FISH panel for myelodysplastic syndrome (MDS) is normalXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count of =< 70,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/uL (> 72 hours since prior platelet transfusion)Xx_NEWLINE_xXPlatelet count >50,000/mm³ within 6 weeks screeningXx_NEWLINE_xXPlatelet count ? 100,000 x10^9/LXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXGENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollmentXx_NEWLINE_xXPlatelet count >= 50,000/mm^3 obtained =< 30 days prior to registrationXx_NEWLINE_xXSubjects must have a platelet count of >= 30,000 to receive immunizations; patients requiring platelet transfusions are eligible to enroll and must have a platelet count >= 30,000 within 72 hours prior to their immunization, or platelet count >= 75,000 without transfusion documented within 30 days for subjects < 12 months post-transplant and within 90 days for subjects 12-35 months post-transplantXx_NEWLINE_xXFOR THE 31 SUBJECTS ENROLLED IN YEAR 1: Subjects must have a platelet count of >= 30,000 to receive the immunizations; patients requiring platelet transfusions are eligible to enroll and must have a platelet count >= 30,000 within 72 hours prior to their immunization, or platelet count >= 75,000 without transfusion documented within 30 days for subjects < 12 months post-transplant and within 90 days for subjects 12-35 months post-transplantXx_NEWLINE_xXPlatelet count >= 100,000/mcLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count > 50,000/mm^3Xx_NEWLINE_xXPlatelet count ?100,000/µLXx_NEWLINE_xXPlatelet count >= 100,000/microliterXx_NEWLINE_xXPlatelet count > 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/ulXx_NEWLINE_xXPlatelet count less than (<) 50,000/millimeter^3 (mm^3), Life expectancy of less than or equal to (<=) 6 monthsXx_NEWLINE_xXANC > 500/?l and platelet count >50,000/?lXx_NEWLINE_xXPlatelet count >= 100,000/microliter obtained =< 45 days prior to randomizationXx_NEWLINE_xXPlatelet count >= 100,000/uL, obtained within 14 days prior to treatment startXx_NEWLINE_xXPlatelet count greater than 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXObtained within 28 days prior to registration: Platelet count (plt) >= 100,000/uLXx_NEWLINE_xXPlatelet count ? 100,000/?LXx_NEWLINE_xXPlatelet count of =< 50,000/uLXx_NEWLINE_xXSubject has a platelet count of less than 50,000 mm3 within 3 days prior to randomization (platelet transfusions are allowed)Xx_NEWLINE_xXPlatelet count of > 100,000Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count ? 100,000/mm^3Xx_NEWLINE_xX- Platelet count of > 50,000/mm3Xx_NEWLINE_xXPlatelet count >= 50,000/mcLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count has to be >= 100,000/uL in patients undergoing biopsyXx_NEWLINE_xXPlatelet count > 50,000/mm^3Xx_NEWLINE_xXPlatelet count >= 50,000Xx_NEWLINE_xXPlatelet count of < 50,000 that cannot be corrected with transfusionXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 150, 000 and < 1,000,000Xx_NEWLINE_xXPlatelet count >= 100,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXThrombocytopenia (platelet count < 50,000)Xx_NEWLINE_xXPlatelet count >= 100,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (without transfusion within 2 weeks prior to cycle 1, day 1)Xx_NEWLINE_xXPlatelet > 50,000/uLXx_NEWLINE_xXPlatelet count >= 100,000/mm^3 (transfusion independent)Xx_NEWLINE_xXPlatelet count >= 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 50,000/mm^3Xx_NEWLINE_xX- Platelet count of > 50,000/mm3Xx_NEWLINE_xXPlatelet count < 100,000/mm^3Xx_NEWLINE_xXPlatelet count > 100,000 cells/mm^3*Xx_NEWLINE_xXPlatelet count > 50,000/mm3Xx_NEWLINE_xXPlatelet count of >= 100,000/mm^3, performed within 28 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count > 100‚000/uLXx_NEWLINE_xXPlatelet count > 100,000/µLXx_NEWLINE_xXPlatelet count >=100,000/mm^3.Xx_NEWLINE_xX